Nab-paclitaxel trials for Metastatic Triple-Negative Breast Carcinoma

All Nab-paclitaxel trials · All Metastatic Triple-Negative Breast Carcinoma trials

Phase breakdown

Recruiting trials studying Nab-paclitaxel for Metastatic Triple-Negative Breast Carcinoma

• High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
  NCT06492759 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
  NCT05422794 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
  NCT03606967 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations

Common questions

How many trials study Nab-paclitaxel for Metastatic Triple-Negative Breast Carcinoma?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.